Applied DNA Regains Compliance with Nasdaq Requirements

Applied DNA Sciences, Inc., a biotechnology company specializing in PCR-based DNA technologies, has announced its compliance with Nasdaq's minimum bid price requirement. On April 7, 2025, the company received confirmation from Nasdaq’s Listing Qualifications Department that its compliance status is restored.

Initially, Applied DNA faced a compliance challenge in November 2024 when its stock price fell below the required $1.00 minimum for over 30 consecutive days. The company successfully addressed this by maintaining a closing bid price of at least $1.00 per share for 16 consecutive business days from March 14 to April 4, 2025.

This development marks the end of the compliance issue, as per Nasdaq’s notification, indicating that the matter is now considered closed.